National Academies Press: OpenBook
« Previous: 5 Crosscutting Themes and Future Directions
Suggested Citation:"6 Closing Remarks." Institute of Medicine. 2011. Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13173.
×

6

Closing Remarks

Jean Hu-Primmer, acting director of FDA Medical Countermeasure Initiative Regulatory Science component, said that one of the goals of the workshop was to help identify anything else that might need to be added to the seven focus areas for Pillar 2 that FDA has defined (Box 6-1). One theme that stands out, she said, is the need for FDA to maintain the staff expertise to be able regulate new cutting-edge products. This is one of the key reasons why it is so important to maintain a robust science program inside FDA. “We strive to keep this program,” she said, “despite continued limited resources, downsizing, and budget cuts.” Professional development is critical, and it is important for FDA researchers to attend

BOX 6-1
Seven Regulatory Science Focus Areas of the FDA MCM Initative (Pillar 2)

  1. Animal models
  2. Biomarkers and clinical immunology
  3. Diagnostics and devices
  4. Private manufacturing and associated assay development
  5. Radiation injury protection and response
  6. Health and scientific computing
  7. Risk communication
Suggested Citation:"6 Closing Remarks." Institute of Medicine. 2011. Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13173.
×

the same scientific seminars and symposiums as academic and industry scientists, to learn about new methods and technologies, and to connect, network, and establish collaborations. Related to this is the need to work collaboratively across government agencies and to leverage those relationships.

While Pillar 2 is just “scraping the tip of the iceberg,” the MCM enterprise is moving in the right direction. The processes that have been set up for internal project proposal reviews, for example, engage all of the MCM enterprise partners. This peer-review process increases the visibility and awareness of partners, thereby creating greater potential for partnerships and collaboration with FDA and across the MCM enterprise as a whole.

The success of the FDA MCM initiative will not be dependent solely upon FDA’s efforts, Hu-Primmer concluded, explaining that it depends on everyone working together, from informal collaborations to competitive grants and contracts, and all options in between.

Suggested Citation:"6 Closing Remarks." Institute of Medicine. 2011. Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13173.
×
Page 79
Suggested Citation:"6 Closing Remarks." Institute of Medicine. 2011. Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13173.
×
Page 80
Next: References »
Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary Get This Book
×
Buy Paperback | $46.00 Buy Ebook | $36.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Whether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures.

During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing Regulatory Science for Medical Countermeasure Development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools.

Advancing Regulatory Science for Medical Countermeasure Development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!